Ergomed Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Ergomed hat ein Gesamteigenkapital von £90.9M und eine Gesamtverschuldung von £0.0, wodurch sich der Verschuldungsgrad auf 0% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen £133.5M bzw. £42.5M. Ergomed Das EBIT des Unternehmens beträgt £20.7M, so dass der Zinsdeckungsgrad 34.1 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von £26.0M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

UK£0

Verschuldung

Zinsdeckungsgrad	34.1x
Bargeld	UK£26.03m
Eigenkapital	UK£90.95m
Gesamtverbindlichkeiten	UK£42.52m
Gesamtvermögen	UK£133.46m

Jüngste Berichte zur Finanzlage

Recent updates

If You Had Bought Ergomed (LON:ERGO) Stock Five Years Ago, You Could Pocket A 643% Gain Today

Feb 22

Has Ergomed plc's (LON:ERGO) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Jan 18

Ergomed plc's (LON:ERGO) Intrinsic Value Is Potentially 20% Below Its Share Price

Dec 13

We Think Ergomed's (LON:ERGO) Statutory Profit Might Understate Its Earnings Potential

Nov 23

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: ERGODie kurzfristigen Aktiva des Unternehmens (£66.9M) übersteigen seine kurzfristigen Passiva (£37.3M).

Langfristige Verbindlichkeiten: ERGODie kurzfristigen Vermögenswerte des Unternehmens (£66.9M) übersteigen seine langfristigen Verbindlichkeiten (£5.2M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: ERGO ist schuldenfrei.

Schulden abbauen: ERGO hatte vor 5 Jahren keine Schulden.

Schuldendeckung: ERGO hat keine Schulden und muss daher nicht durch den operativer Cashflow gedeckt werden.

Zinsdeckung: ERGO hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.

Ergomed Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Ergomed Confirms Expected Scheme Timetable

Recent updates

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Now 20% undervalued after recent price drop

Is It Time To Consider Buying Ergomed plc (LON:ERGO)?

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ergomed plc, Annual General Meeting, Jun 22, 2023

At UK£9.74, Is Ergomed plc (LON:ERGO) Worth Looking At Closely?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Ergomed plc to Report Fiscal Year 2022 Results on Mar 21, 2023

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Ergomed Announces Two Senior Appointments to its Executive Team

Ergomed Strengthens Executive Management Team

Ergomed Strengthens Executive Management Team

Ergomed plc (LON:ERGO) Shares Could Be 21% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: UK£0.15 (vs UK£0.14 in 1H 2021)

Ergomed plc to Report First Half, 2022 Results on Sep 27, 2022

Investor sentiment improved over the past week

Should You Be Adding Ergomed (LON:ERGO) To Your Watchlist Today?

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc Appoints Anne Whitaker as Independent Non-Executive Director

Full year 2021 earnings: EPS misses analyst expectations

Ergomed plc, Annual General Meeting, Jun 10, 2022

Consensus EPS estimates increase by 11%

Consensus forecasts updated

Less than half of directors are independent

Now 21% undervalued

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Full year 2021 earnings: EPS misses analyst expectations

Does Ergomed (LON:ERGO) Deserve A Spot On Your Watchlist?

John Dawson, Cbe Joins the Board of Ergomed plc as Independent Non-Executive Director and Chair of the Audit Committee

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc to Report Fiscal Year 2021 Results on Mar 29, 2022

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

Ergomed plc (AIM:ERGO) acquired Adamas Consulting Ltd. at an enterprise value of £24.2 million.

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

Investor sentiment deteriorated over the past week

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Ergomed (LON:ERGO) Passed With Ease

First half 2021 earnings released: EPS UK£0.14 (vs UK£0.089 in 1H 2020)

Calculating The Intrinsic Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out Ergomed (LON:ERGO) Before It's Too Late

Getting In Cheap On Ergomed plc (LON:ERGO) Might Be Difficult

Ergomed plc (LON:ERGO) Shares Could Be 31% Above Their Intrinsic Value Estimate

Price target increased to UK£13.65

Non-Executive Director has left the company

Investor sentiment improved over the past week

Do Ergomed's (LON:ERGO) Earnings Warrant Your Attention?

Full year 2020 earnings released

Price target increased to UK£12.70

If You Had Bought Ergomed (LON:ERGO) Stock Five Years Ago, You Could Pocket A 643% Gain Today

New 90-day high: UK£12.45

Ergomed plc to Report Fiscal Year 2020 Results on Mar 23, 2021

Price target raised to UK£11.85

Has Ergomed plc's (LON:ERGO) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

New 90-day high: UK£10.55

Ergomed plc (AIM:ERGO) acquired MedSource Consulting Inc. for $25 million.

Ergomed plc's (LON:ERGO) Intrinsic Value Is Potentially 20% Below Its Share Price

New 90-day high: UK£9.50

We Think Ergomed's (LON:ERGO) Statutory Profit Might Understate Its Earnings Potential

New 90-day high: UK£8.52

New 90-day high: UK£8.45

New 90-day high: UK£7.70